BRIEF-Jounce Therapeutics To Be Acquired By Concentra Biosciences

Reuters2023-03-27

March 27 (Reuters) - Jounce Therapeutics Inc :

* JOUNCE THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $1.85 IN CASH PER SHARE PLUS CONTINGENT VALUE RIGHTS

* JOUNCE THERAPEUTICS - BOARD OF DIRECTORS IS NO LONGER RECOMMENDING PROPOSED ALL-SHARE MERGER TRANSACTION WITH REDX PHARMA PLC

* JOUNCE THERAPEUTICS INC - IMPLEMENTING A WORKFORCE REDUCTION OF APPROXIMATELY 84% OF ITS EMPLOYEES

* JOUNCE THERAPEUTICS INC - REDUCTION IS EXPECTED TO BE COMPLETED WITHIN NEXT MONTH AND JOUNCE WILL INCUR RESTRUCTURING COSTS TOTALING ABOUT $6.5 MILLION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2322429580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-03-27 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2322429580","market":"us","top_or_hot":-1,"title":"BRIEF-Jounce Therapeutics To Be Acquired By Concentra Biosciences","media":"Reuters","content":"<html><body><p>March 27 (Reuters) - Jounce Therapeutics Inc   :</p><p>   * JOUNCE THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $1.85 IN CASH PER SHARE PLUS CONTINGENT VALUE RIGHTS</p><p>   * JOUNCE THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $1.85 IN CASH PER SHARE PLUS CONTINGENT VALUE RIGHTS</p><p>   * JOUNCE THERAPEUTICS - BOARD OF DIRECTORS IS NO LONGER RECOMMENDING PROPOSED ALL-SHARE MERGER TRANSACTION WITH <a href=\"https://laohu8.com/S/REDX.UK\">REDX PHARMA PLC</a></p><p>   * JOUNCE THERAPEUTICS INC - IMPLEMENTING A WORKFORCE REDUCTION OF APPROXIMATELY 84% OF ITS EMPLOYEES</p><p>   * JOUNCE THERAPEUTICS INC - REDUCTION IS EXPECTED TO BE COMPLETED WITHIN NEXT MONTH AND JOUNCE WILL INCUR RESTRUCTURING COSTS TOTALING ABOUT $6.5 MILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Jounce Therapeutics To Be Acquired By Concentra Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Jounce Therapeutics To Be Acquired By Concentra Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-27 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 27 (Reuters) - Jounce Therapeutics Inc   :   * JOUNCE THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $1.85 IN CASH PER SHARE PLUS CONTINGENT VALUE RIGHTS   * ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APR","symbol_name":"Apria, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2322429580","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2322429580","pubTimestamp":1679922542,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 27 (Reuters) - Jounce Therapeutics Inc   :   * JOUNCE THERAPEUTICS ENTERS INTO AGREEMENT TO BE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc.","BK4139":"生物科技","ONTF":"ON24, Inc.","BK4023":"应用软件","BK4007":"制药","BK4196":"保健护理服务","LHDX":"Lucira Health, Inc.","LABP":"Landos Biopharma, Inc.","CGEM":"Cullinan Therapeutics","BK4082":"医疗保健设备"},"translate_title":"Concentra Biosciences将收购的短暂颠簸疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNCE":0.9,"ONTF":0.9,"APR":0.82,"CGEM":0.82,"LABP":0.82,"LHDX":0.82,"SANA":0.82},"content_text":"March 27 (Reuters) - Jounce Therapeutics Inc   :   * JOUNCE THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $1.85 IN CASH PER SHARE PLUS CONTINGENT VALUE RIGHTS   * JOUNCE THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $1.85 IN CASH PER SHARE PLUS CONTINGENT VALUE RIGHTS   * JOUNCE THERAPEUTICS - BOARD OF DIRECTORS IS NO LONGER RECOMMENDING PROPOSED ALL-SHARE MERGER TRANSACTION WITH REDX PHARMA PLC   * JOUNCE THERAPEUTICS INC - IMPLEMENTING A WORKFORCE REDUCTION OF APPROXIMATELY 84% OF ITS EMPLOYEES   * JOUNCE THERAPEUTICS INC - REDUCTION IS EXPECTED TO BE COMPLETED WITHIN NEXT MONTH AND JOUNCE WILL INCUR RESTRUCTURING COSTS TOTALING ABOUT $6.5 MILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2322429580"}